| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from OCS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from OCS graph: ction with its spin-off from Novart… |
| NVSEF |
Novartis AG |
72%
|
ction with its spin-off from Novartis. 130 We are deemed the owner of any inventions that are (a) created solely by or on behalf of us pursuant to the Novartis Agreement and (b) severable from the li… |
| ALC |
Alcon Inc. |
62%
|
Reciprocal relationship from ALC graph: Reciprocal relationship from OCS graph: Reciprocal relationship from ALC graph: Reciprocal relationship from OCS graph: Reciprocal relationship from ALC graph:… |
| ALCON-RESEARCH-LTD |
ALCON-RESEARCH-LTD |
62%
|
welve months from the date that this Annual Report is filed with the SEC without additional capital or drawdown from our loan facility. We have based our estimate on assumptions that may prove to be … |
| BAC |
Bank of America Corporation |
62%
|
Reciprocal relationship from BAC graph: Reciprocal relationship from OCS graph: Reciprocal relationship from BAC graph: Reciprocal relationship from OCS graph: Reciprocal relationship from BAC graph:… |
| BOFA-SECURITIES-INC |
BOFA-SECURITIES-INC |
62%
|
Offering On February 14, 2025, we entered into an underwriting agreement with BofA Securities Inc. and Leerink Partners LLC, as a representative of the several underwriters in connection with an offe… |
| C-GROUP |
C-GROUP |
62%
|
at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates of exchange prevailing at reporting date. Any gains or losses from… |
| COORDINATION-GROUP |
COORDINATION-GROUP |
62%
|
under the Novartis Agreement and we fail to remedy such failure within a specified period of time; (ii) an insolvency event occurs; (iii) we materially breach our obligations under the Novartis Agree… |
| DUAL-LISTED-PUBLIC-COMPANY |
DUAL-LISTED-PUBLIC-COMPANY |
62%
|
obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requir… |
| EUROPEAN-BIOTECH-ACQUISITION-CORP |
EUROPEAN-BIOTECH-ACQUISITION-CORP |
62%
|
ment comprise all of the senior management of the combined company. • Business Combination accounted for within the scope of IFRS 2 EBAC was a Special Purpose Acquisition Company and therefore does n… |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
fA Securities Inc. and Leerink Partners LLC, as a representative of the several underwriters in connection with an offering of 5,000,000 of our ordinary shares, CHF 0.01 nominal value per share, at a… |
| NOVARTIS-TECHNOLOGY-LLC |
NOVARTIS-TECHNOLOGY-LLC |
62%
|
welve months from the date that this Annual Report is filed with the SEC without additional capital or drawdown from our loan facility. We have based our estimate on assumptions that may prove to be … |
| OCULIS-GROUP |
OCULIS-GROUP |
62%
|
icare and Medicaid. The term “remuneration” has been broadly interpreted to include anything of value. The ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute… |
| OCULIS-HK-LIMITED |
OCULIS-HK-LIMITED |
62%
|
icare and Medicaid. The term “remuneration” has been broadly interpreted to include anything of value. The ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute… |
| OCULIS-MERGER-SUB-II-COMPANY |
OCULIS-MERGER-SUB-II-COMPANY |
62%
|
icare and Medicaid. The term “remuneration” has been broadly interpreted to include anything of value. The ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute… |
| OCULIS-US-INC |
OCULIS-US-INC |
62%
|
icare and Medicaid. The term “remuneration” has been broadly interpreted to include anything of value. The ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute… |
| SPECIAL-PURPOSE-ACQUISITION-COMPANY |
SPECIAL-PURPOSE-ACQUISITION-COMPANY |
62%
|
ment comprise all of the senior management of the combined company. • Business Combination accounted for within the scope of IFRS 2 EBAC was a Special Purpose Acquisition Company and therefore does n… |
| STRUCTURE-OCULIS-HOLDING-AG |
STRUCTURE-OCULIS-HOLDING-AG |
62%
|
icare and Medicaid. The term “remuneration” has been broadly interpreted to include anything of value. The ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute… |
| UK-LIMITED |
UK-LIMITED |
62%
|
BAC public warrant (“ BCA Public Warrants ”) and EBAC private placement warrant (“ BCA Private Warrants ”) ceased to be a warrant with respect to EBAC ordinary shares and were assumed by Oculis as wa… |
